Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors.
Eleven dogs with cutaneous mast cell tumors (MCTs) were treated with surgery and iridium-192 ((192)Ir) interstitial brachytherapy. Minimum tumor doses ranged from 47.2 to 63.3 Gy. Treated tumors were classified as grade II (n=7) or III (n=4). Five dogs had recurrences with a median progression-free interval of 1391 days, and six dogs had no recurrence at a median follow-up time of 942 days. Acute adverse effects were well tolerated, and late effects were mild. One dog developed a second tumor of a different cell type in the radiation treatment field.
Northrup
Nicole C
NC
Department of Small Animal Medicine and Surgery, Comparative Oncology Program, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602, USA.
Roberts
Royce E
RE
Harrell
Todd W
TW
Allen
Karen L
KL
Howerth
Elizabeth W
EW
Gieger
Tracy L
TL
D000818:Animals; D001918:Brachytherapy / Q000379:methods / Q000662:veterinary*; D004283:Dog Diseases / Q000473:pathology / Q000532:radiotherapy*; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D005260:Female; D007496:Iridium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012515:Mast-Cell Sarcoma / Q000473:pathology / Q000532:radiotherapy / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000662:veterinary; D009367:Neoplasm Staging / Q000662:veterinary; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000662:veterinary*; D016896:Treatment Outcome
D007496:Iridium Radioisotopes